Source:http://linkedlifedata.com/resource/pubmed/id/11165130
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2001-2-22
|
pubmed:abstractText |
We retrospectively analysed the incidence and risk factors of treatment-related death in the treatment of chemotherapy- and thoracic radiotherapy-naïve patients with lung cancer. Between July 1992 and December 1997, 1799 patients were diagnosed as having lung cancer in our hospital and 926 patients received chemotherapy and/or thoracic radiotherapy. 25 patients (2.7%) died from toxicity of the treatment, 10 from pneumonia, 7 from radiation pneumonitis, 6 from sepsis, 1 from perforation of the small intestine and 1 for an unknown reason. 18 patients (2.3%) died from chemotherapy-related toxicity. The incidence of treatment-related death (TRD) from chemotherapy was highly correlated with the performance status (PS), PS 0: 0.7%, PS 1: 2.2%, PS 2: 4.0%, PS 3: 7.7% and PS 4: 25% (P=0.004). 7 patients (1.6%) died from pneumonitis after thoracic radiotherapy. Multivariate analyses demonstrated that poor PS (relative risk (RR): 1.95, 95% confidence interval (CI): 1.05-3.65, P=0.034) and chemotherapy using the cisplatin+vindesine+mitomycin C regimen (RR: 9.36, 95% CI: 1.29-68.0, P=0.027) are associated with treatment-related death from chemotherapy. Pulmonary fibrosis identified on a plain chest X-ray film (RR: 165.7, 95% CI: 8.79-3122, P<0.001), the combination of cisplatin+irinotecan (RR: 120.5, 95% CI: 2.90-4993, P=0.012), advanced age (RR: 1.17, 95% CI: 1.002-1.37, P=0.047), and elevated lactate dehydrogenase (LDH) (RR: 10.4, 95% CI: 1.20-90.2, P=0.033) were also associated with treatment-related death from thoracic radiotherapy. The administration of mitomycin C in addition to cisplatin-based regimens for patients with lung cancer should be carefully considered.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
54-63
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11165130-Adult,
pubmed-meshheading:11165130-Aged,
pubmed-meshheading:11165130-Aged, 80 and over,
pubmed-meshheading:11165130-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11165130-Female,
pubmed-meshheading:11165130-Humans,
pubmed-meshheading:11165130-Lung Neoplasms,
pubmed-meshheading:11165130-Male,
pubmed-meshheading:11165130-Middle Aged,
pubmed-meshheading:11165130-Radiotherapy,
pubmed-meshheading:11165130-Retrospective Studies,
pubmed-meshheading:11165130-Risk Factors,
pubmed-meshheading:11165130-Survival Analysis,
pubmed-meshheading:11165130-Time Factors
|
pubmed:year |
2001
|
pubmed:articleTitle |
Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer.
|
pubmed:affiliation |
Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, 6-5-1 Kashiwanoha, Kashiwa-City, 277-8577, Chiba, Japan. yohe@gan2.ncc.go.jp
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|